Physician profile
Kayla K Sayer
NPI 1003563669
$1,138.61
in general payments reported to CMS, 2019-2025
12 companies · $979 in 2025
The $979 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $11.74 · 2023: $49.45 · 2024: $98.15 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.60 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.18 | 2024-2025 | Ozempic, Rybelsus, Sogroya |
| Medtronic, INC. | $285.96 | 2023-2025 | Minimed 780g, Minimed 770g |
| Insulet Corporation | $197.73 | 2025 | Omnipod |
| Lilly USA, LLC | $104.31 | 2022-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $68.68 | 2024-2025 | |
| Pfizer INC. | $52.44 | 2025 | |
| Ascendis Pharma Endocrinology INC | $43.89 | 2025 | Skytrofa |
| Eton Pharmaceuticals, INC. | $23.97 | 2025 | Alkindi, Khindivi, Increlex |
| Recordati_rare_diseases_inc. | $21.86 | 2025 | Isturisa |
| Sanofi-Aventis U.S. LLC | $17.55 | 2025 | |
| Dexcom, INC. | $16.62 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $14.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Sayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.